Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033108 · ClinicalTrials.gov registry record · Phase 2
Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
A Phase 2 study of Stargardt Disease and Macular Atrophy, sponsored by Kubota Vision.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT03033108: Completed Phase 2 study of Stargardt Disease and Macular Atrophy, sponsored by Kubota Vision.
NCT03033108 is a Phase 2 study of Stargardt Disease and Macular Atrophy that has completed, run by Kubota Vision. The registered enrollment target is 23 participants, below the 90-participant average among 16 other Stargardt Disease trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03033108, a Phase 2 study of Stargardt Disease and Macular Atrophy, has completed, sponsored by Kubota Vision.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pharmacodynamics study of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease.
Primary Outcome
Percent suppression compared to baseline of rod b-wave amplitude recovery after a photobleaching light.
Conditions Studied
Interventions
- DRUG Emixustat
Study Locations (1)
Texas
- - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
What the finished NCT03033108 record still lists
NCT03033108 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 90-participant average among 16 other Stargardt Disease trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Stargardt Disease appearing as the primary indexed condition, and to 1 intervention - of which Emixustat is the first listed.
NCT03033108 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03033108 about?
NCT03033108 is a clinical study titled "Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease". This is a pharmacodynamics study of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease.
What is the current status of trial NCT03033108?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2017-01. Estimated completion is 2017-12.
What conditions does trial NCT03033108 study?
This clinical trial studies the following conditions: Stargardt Disease, Macular Atrophy.
What interventions are being tested in trial NCT03033108?
The interventions under investigation include: Emixustat (DRUG).
Who is sponsoring clinical trial NCT03033108?
This trial is sponsored by Kubota Vision, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03033108 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03033108's enrollment target sits among peer trials
23 13th of 16 higher than 4 of 16 other Stargardt Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stargardt Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
RECRUITING · Phase 2
-
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
ACTIVE NOT RECRUITING · Phase 2
-
An Observational Study in Children and Adults With Stargardt Disease
RECRUITING
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
RECRUITING
-
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia